This is in contrast to the Eμ-RET-driven leukaemia, that is driven by an Eμ-enhancer and lacks a myeloid potential in several publications41, 53, 54, and which retains stable B lineage commitment even with in vivo CD19-CAR immune pressure or in vitro deletion of Ebf1 and Pax5. This evidence concerns the gene PAX5 and leukemia.